Clinical considerations for routine auditory and vestibular monitoring in patients with cystic fibrosis

Angela C. Garinis, Gayla L. Poling, Ronald C. Rubenstein, Dawn Konrad-Martin, Timothy E. Hullar, David M. Baguley, Holly L. Burrows, Jennifer A. Chisholm, Amy Custer, Laura Dreisbach Hawe, Lisa L. Hunter, Theodore K. Marras, Candice E. Ortiz, Lucretia Petersen, Peter S. Steyger, Kevin Winthrop, Erika M. Zettner, Khaya Clark, Michelle Hungerford, Jay J. VachhaniCarmen C. Brewer

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Purpose: Specific classes of antibiotics, such as aminoglycosides, have well-established adverse events producing permanent hearing loss, tinnitus, and balance and/or vestibular problems (i.e., ototoxicity). Although these antibiotics are frequently used to treat pseudomonas and other bacterial infections in patients with cystic fibrosis (CF), there are no formalized recommendations describing approaches to implementation of guideline adherent ototoxicity monitoring as part of CF clinical care. Method: This consensus statement was developed by the International Ototoxicity Management Working Group (IOMG) Ad Hoc Committee on Aminoglycoside Antibiotics to address the clinical need for ototoxicity management in CF patients treated with known ototoxic medications. These clinical protocol considerations were created using consensus opinion from a community of international experts and available evidence specific to patients with CF, as well as published national and international guidelines on ototoxicity monitoring. Results: The IOMG advocates four clinical recommendations for implementing routine and guideline adherent ototoxicity management in patients with CF. These are (a) including questions about hearing, tinnitus, and balance/vestibular problems as part of the routine CF case history for all patients; (b) utilizing timely point-of-care measures; (c) establishing a baseline and conducting posttreatment evaluations for each course of intravenous ototoxic drug treatment; and (d) repeating annual hearing and vestibular evaluations for all patients with a history of ototoxic antibiotic exposure. Conclusion: Increased efforts for implementation of an ototoxicity management program in the CF care team model will improve identification of ototoxicity signs and symptoms, allow for timely therapeutic follow-up, and provide the clinician and patient an opportunity to make an informed decision about potential treatment modifications to minimize adverse events.

Original languageEnglish (US)
Pages (from-to)800-809
Number of pages10
JournalAmerican Journal of Audiology
Volume30
Issue number3S
DOIs
StatePublished - Oct 2021

All Science Journal Classification (ASJC) codes

  • Speech and Hearing

Fingerprint

Dive into the research topics of 'Clinical considerations for routine auditory and vestibular monitoring in patients with cystic fibrosis'. Together they form a unique fingerprint.

Cite this